Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;161(3):728-737.
doi: 10.1016/j.chest.2021.10.021. Epub 2021 Oct 23.

Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study

Affiliations

Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study

Claire M Nolan et al. Chest. 2022 Mar.

Abstract

Background: The adherence to and clinical efficacy of pulmonary rehabilitation in idiopathic pulmonary fibrosis (IPF), particularly in comparison with COPD, remains uncertain. The objectives of this real-world study were to compare the responses of patients with IPF with a matched group of patients with COPD undergoing the same supervised, outpatient pulmonary rehabilitation program and to determine whether pulmonary rehabilitation is associated with survival in IPF.

Research question: Do people with IPF improve to the same extent with pulmonary rehabilitation as a matched group of individuals with COPD, and are noncompletion of or nonresponse to pulmonary rehabilitation, or both, associated with 1-year all-cause mortality in IPF?

Study design and methods: Using propensity score matching, 163 patients with IPF were matched 1:1 with a control group of 163 patients with COPD referred for pulmonary rehabilitation. We compared between-group pulmonary rehabilitation completion rates and response. Survival status in the IPF cohort was recorded over 1 year after pulmonary rehabilitation discharge. Cox proportional hazards regression explored the association between pulmonary rehabilitation status and all-cause mortality.

Results: Similar pulmonary rehabilitation completion rates (IPF, 69%; COPD, 63%; P = .24) and improvements in exercise response were observed in both groups with no significant mean between-group differences in incremental shuttle walk test (ISWT) change (mean, 2 m [95% CI, -18 to 22 m]). Pulmonary rehabilitation noncompletion (hazard ratio [HR], 5.62 [95% CI, 2.24-14.08]) and nonresponse (HR, 3.91 [95% CI, 1.54-9.93]) were associated independently with increased 1-year all-cause mortality in IPF.

Interpretation: This real-word study demonstrated that patients with IPF have similar completion rates and magnitude of response to pulmonary rehabilitation compared with a matched group of patients with COPD. In IPF, noncompletion of and nonresponse to pulmonary rehabilitation were associated with increased all-cause mortality. These data reinforce the benefits of pulmonary rehabilitation in patients with IPF.

Keywords: COPD; idiopathic pulmonary fibrosis; prognosis; pulmonary rehabilitation.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Flow chart showing participant recruitment and reasons for PR noncompletion. ILD = interstitial lung disease; IPF = idiopathic pulmonary fibrosis; PR = pulmonary rehabilitation; RIP = rest in peace.
Figure 2
Figure 2
Graph showing the mean (95% CI) change in ISWT distance in participants with IPF and COPD (unmatched analysis). IPF = idiopathic pulmonary fibrosis; ISWT = incremental shuttle walk test; MID = minimal important difference.
Figure 3
Figure 3
Kaplan-Meier curve and at-risk table demonstrating time to all-cause mortality at 1 year according to PR status, with table depicting the numbers at risk. PR = pulmonary rehabilitation.

Comment in

Similar articles

Cited by

References

    1. Fell C.D. Idiopathic pulmonary fibrosis: phenotypes and comorbidities. Clin Chest Med. 2012;33(1):51–57. - PubMed
    1. Holland A.E., Fiore J.F., Bell E.C., et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014;19(8):1215–1221. - PubMed
    1. Noble P.W., Albera C., Bradford W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. - PubMed
    1. Richeldi L., du Bois R.M., Raghu G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. - PubMed
    1. McCarthy B., Casey D., Devane D., Murphy K., Murphy E., Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2) - PMC - PubMed

Publication types

MeSH terms